CERo Therapeutics Holdings
CERo Therapeutics Holdings
CERO
NASDAQ
1.70
USD
-17.07%
About
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy.
Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 2.9M |
| Three Month Average Volume | 110.9M |
| High Low | |
| Fifty-Two Week High | 12.8 USD |
| Fifty-Two Week Low | 0.1222 USD |
| Fifty-Two Week High Date | 06 Feb 2024 |
| Fifty-Two Week Low Date | 07 Aug 2024 |
| Price and Volume | |
| Current Price | 0.1272 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -23.21% |
| Thirteen Week Relative Price Change | -87.22% |
| Twenty-Six Week Relative Price Change | -96.09% |
| Fifty-Two Week Relative Price Change | -99.06% |
| Year-to-Date Relative Price Change | -99.02% |
| Price Change | |
| One Day Price Change | -2.00% |
| Thirteen Week Price Change | -86.32% |
| Twenty-Six Week Price Change | -95.70% |
| Five Day Price Change | -8.62% |
| Fifty-Two Week Price Change | -98.82% |
| Year-to-Date Price Change | -98.84% |
| Month-to-Date Price Change | -18.46% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.92261 USD |
| Book Value Per Share (Most Recent Quarter) | -0.92261 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.92261 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.92261 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.44439 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.38848 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.3796 USD |
| Normalized (Last Fiscal Year) | -0.38848 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.38848 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.3796 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.38848 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.3796 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.01551 USD |
| Cash Per Share (Most Recent Quarter) | 0.01551 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.38848 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.38427 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.23085 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -246.76% |
| EPS Change (Trailing Twelve Months) | -1,160.71% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 1.5M |
| Net Debt (Last Fiscal Year) | 1.5M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -1,523,600 |
| Free Cash Flow (Trailing Twelve Months) | -1,523,600 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -9.96% |
| Return on Assets (Trailing Twelve Months) | -9.96% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -33.80% |
| Return on Investment (Trailing Twelve Months) | -33.80% |
| Return on Investment (5 Year) | -99,999.99% |